



TIMELINE	SAMPLE	TESTING	GROUP TEST
ORDERED	NAME	CLIENT	VIALS TESTED
October 24, 2026	Retatrutide 30 mg	Lab2Vial	1 vial, shared result
RECEIVED	EXPECTED	TEST TYPE	CONTRIBUTORS
October 28, 2026	Retatrutide	Content & purity	3 people
ANALYZED	AMOUNT	METHOD	SHARED BY
October 29, 2026	1 vial, lyophilized powder	HPLC-UV	Jose Gonzalez, Andre, Dustin Ogando

CONTENT, HOW MUCH IS IN IT

30.74 mg

Label claim: 30 mg


PURITY, HOW CLEAN IT IS

>99.9%

by HPLC-UV peak area

CHROMATOGRAM

HPLC-UV



● 18.00 min, Retatrutide, >99.9%

ANALYST COMMENTS

White lyophilized powder, blue-cap vial, received sealed. Unlabeled vial; label claim taken from the order.

ANALYST SIGNATURE

Max Barrett

Lab Director, PuriLab Analytical

Analysis date: October 29, 2026

VERIFICATION CODE

RT-LRDR-B8EZ

Verify at purilab.org/verify/RT-LRDR-B8EZ

SCAN TO VERIFY



RT-LRDR-B8EZ

Results apply solely to the sample as received and are not representative of any larger lot, batch, or production run. Findings are limited to the analytes stated above. PuriLab Analytical is an independent testing laboratory, is not CLIA certified or ISO 17025 accredited, does not sell or distribute any substance, and makes no representation as to the safety, legality, or fitness of any material for any use.